2013•Autoimmunity ReviewsRequires access

Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Horacio Berman, Ignasi Rodríguez‐Pintó, Ricard Cervera, Nathalie Morel, N. Costedoat‐Chalumeau, Doruk Erkan, Yehuda Shoenfeld, Gerard Espinosa

Open publisher page 256 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 256 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rituximab, Catastrophic antiphospholipid syndrome, Medicine, Antiphospholipid syndrome, Regimen, Catastrophic illness, Internal medicine, Thrombosis

Back to paper search Browse research topics Original source

Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab — Research Paper | ScholarLens